PMID- 30187662 OWN - NLM STAT- MEDLINE DCOM- 20190409 LR - 20190409 IS - 1756-185X (Electronic) IS - 1756-1841 (Linking) VI - 21 IP - 11 DP - 2018 Nov TI - Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis - results from the CHIKARA study. PG - 1962-1969 LID - 10.1111/1756-185X.13335 [doi] AB - AIM: Patients with rheumatoid arthritis (RA) show lower muscle mass and a higher prevalence of sarcopenia than healthy individuals. Correlations between sarcopenia and disease activity, physical function, laboratory data and body composition at baseline were investigated in a prospective, observational study (CHIKARA study) of RA patients. METHODS: Body composition was measured using a bioelectrical impedance analyzer. Parameters were compared between sarcopenia and non-sarcopenia groups, and correlations between sarcopenia and Disease Activity Score of 28 joints - erythrocyte sedimentation rate (DAS28-ESR), modified health assessment questionnaire, treatment, and laboratory data, including matrix metalloproteinase 3 (MMP3), were investigated. RESULTS: The participants were 100 patients with RA (women, 78%; mean age, 66.1 years). Mean disease duration was 5.5 years, DAS28-ESR was 3.55 and the prevalence of sarcopenia was 28%. Median C-reactive protein (CRP) and MMP3 were significantly higher in the sarcopenia group (0.21 mg/dL and 103.4 ng/mL) than in the non-sarcopenia group (0.11 mg/dL and 70.3 ng/mL). Sarcopenia was negatively correlated with weight, body mass index (BMI), muscle mass, body fat mass, estimated bone mass and basal metabolic rate, and positively correlated with Steinbrocker stage, CRP and MMP3 on univariate analyses. BMI, body fat mass and MMP3 were independently associated with sarcopenia on multivariate logistic regression analysis. When MMP3 was >/= 90.7 ng/mL, the odds ratio for sarcopenia was increased 3.1-fold compared with < 90.7 ng/mL (P = 0.018). CONCLUSION: The prevalence of sarcopenia was 28% in patients with RA whose disease activity was mild. Low BMI, high fat mass and high MMP3 were independently associated with sarcopenia. MMP3 might be a useful marker for sarcopenia in patients with RA. CI - (c) 2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. FAU - Tada, Masahiro AU - Tada M AUID- ORCID: 0000-0003-3161-3929 AD - Department of Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan. FAU - Yamada, Yutaro AU - Yamada Y AD - Department of Orthopaedic Surgery, Osaka City University Medical School, Osaka, Japan. FAU - Mandai, Koji AU - Mandai K AD - Department of Orthopaedic Surgery, Osaka City University Medical School, Osaka, Japan. FAU - Hidaka, Noriaki AU - Hidaka N AD - Department of Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan. LA - eng GR - Japan Osteoporosis Foundation/ PT - Comparative Study PT - Journal Article PT - Observational Study DEP - 20180905 PL - England TA - Int J Rheum Dis JT - International journal of rheumatic diseases JID - 101474930 RN - 0 (Biomarkers) RN - EC 3.4.24.17 (MMP3 protein, human) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) SB - IM MH - Adiposity MH - Aged MH - Aged, 80 and over MH - Arthritis, Rheumatoid/blood/diagnosis/*enzymology/epidemiology MH - Biomarkers/blood MH - *Body Composition MH - Body Mass Index MH - Electric Impedance MH - Female MH - Health Status MH - Humans MH - Japan/epidemiology MH - Male MH - Matrix Metalloproteinase 3/*blood MH - Middle Aged MH - Prevalence MH - Prospective Studies MH - Sarcopenia/blood/diagnosis/*enzymology/epidemiology OTO - NOTNLM OT - bioelectrical impedance analysis OT - matrix metalloprotease 3 OT - prospective observational study OT - rheumatoid arthritis OT - sarcopenia EDAT- 2018/09/07 06:00 MHDA- 2019/04/10 06:00 CRDT- 2018/09/07 06:00 PHST- 2018/09/07 06:00 [pubmed] PHST- 2019/04/10 06:00 [medline] PHST- 2018/09/07 06:00 [entrez] AID - 10.1111/1756-185X.13335 [doi] PST - ppublish SO - Int J Rheum Dis. 2018 Nov;21(11):1962-1969. doi: 10.1111/1756-185X.13335. Epub 2018 Sep 5.